Chemo Regimen for Ovarian Cancer Charlotte NC

Dose-dense chemotherapy improves survival in women with advanced ovarian cancer, Japanese researchers say. Currently, paclitaxel and carboplatin given every three weeks is considered standard first-line chemotherapy for advanced epithelial ovarian cancer. However, dose-dense weekly treatment with paclitaxel is seen as a way to increase progression-free and overall survival in these patients in Charlotte, according to the new study findings.

Jay Levy, MD
(704) 540-3667
3125 Springbank Ln
Charlotte, NC
Business
Pediatric Urology Associates PA
Specialties
Urology

Data Provided by:
Daniel Lee Watson
(704) 372-5180
201 Queens Rd
Charlotte, NC
Specialty
Urology

Data Provided by:
Manish Nalin Damani, MD
(704) 375-5755
1718 E 4th St Ste 807
Charlotte, NC
Specialties
Urology
Gender
Male
Education
Medical School: Northeastern Oh Univs Coll Of Med, Rootstown Oh 44272
Graduation Year: 1995

Data Provided by:
Samuel Jay Peretsman
(704) 372-5180
201 Queens Rd
Charlotte, NC
Specialty
Urology

Data Provided by:
Michael Raymond O'Neill, MD
(704) 375-5755
1718 E 4th St Ste 807
Charlotte, NC
Specialties
Urology
Gender
Male
Education
Medical School: Bowman Gray Sch Of Med Of Wake Forest Univ, Winston-Salem Nc 27157
Graduation Year: 1976

Data Provided by:
Zane Basrawala
(704) 370-2076
1518 E 3rd St
Charlotte, NC
Specialty
Urology

Data Provided by:
Pierce B Irby III, MD
(704) 355-8686
1416 E Morehead St Ste 101
Charlotte, NC
Specialties
Urology
Gender
Male
Education
Medical School: Uniformed Services Univ Of The Hlth Sci, Bethesda Md 20814
Graduation Year: 1983

Data Provided by:
William Charles Rice
(704) 372-5180
201 Queens Rd
Charlotte, NC
Specialty
Urology

Data Provided by:
Luis Manuel Perez, MD
(704) 376-5636
1718 E 4th St Ste 805
Charlotte, NC
Specialties
Urology
Gender
Male
Education
Medical School: A Einstein Coll Of Med Of Yeshiva Univ, Bronx Ny 10461
Graduation Year: 1988

Data Provided by:
Jacques Paul Ganem, MD
(704) 375-5755
1718 E 4th St Ste 807
Charlotte, NC
Specialties
Urology
Gender
Male
Education
Medical School: Suny-Hlth Sci Ctr At Brooklyn, Coll Of Med, Brooklyn Ny 11203
Graduation Year: 1993

Data Provided by:
Data Provided by:

Chemo Regimen for Ovarian Cancer

Provided By:

SUNDAY, Sept. 20 (HealthDay News) -- Dose-dense chemotherapy improves survival in women with advanced ovarian cancer, Japanese researchers say.

Currently, paclitaxel and carboplatin given every three weeks is considered standard first-line chemotherapy for advanced epithelial ovarian cancer. However, dose-dense weekly treatment with paclitaxel is seen as a way to increase progression-free and overall survival in these patients, according to the new study findings.

This phase 3 study of 637 women compared the two approaches. The participants had advanced epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.

The 320 patients in the conventional regimen group received six cycles of paclitaxel (180 milligrams per meter squared; three-hour intravenous infusion). The 317 patients in the dose-dense group received paclitaxel (80 milligrams per meter squared; one-hour intravenous infusion) on days one, eight and 15. Both groups received carboplatin on day one of a 21-day cycle.

The patients in the dose-dense group had longer median progression-free survival than those in the standard treatment group (28 months versus 17 months), and longer overall survival at three years (72 percent versus 65 percent). This means that women in the dose-dense group had a 29 percent lower risk of cancer progression and a 25 percent lower risk of death, the authors explained.

Toxicity forced 113 patients in the dose-dense group and 69 patients in the conventional therapy group to stop treatment, the researchers noted. Severe anemia occurred in 214 patients (69 percent) in the dose-dense group and in 137 (44 percent) of the standard therapy group.

The survival benefits seen in the dose-dense group are rare in patients with advanced ovarian cancer, and this regimen offers a new treatment option for women with advanced epithelial ovarian cancer, concluded Dr. Noriyuki Katsumata, of the National Cancer Center Hospital in Tokyo, and colleagues.

The study, published in an upcoming print issue of The Lancet, was released online Sunday to coincide with the European Cancer Organization meeting held Sept. 20 to 24 in Berlin.

"The use of such dose-dense therapy should be decided on an individual basis together with other options for women with advanced-stage ovarian cancer," Dr. Michael A. Bookman, of the Arizona Cancer Center in Tucson, wrote in an accompanying commentary in The Lancet.

More information

The U.S. National Cancer Institute has more about ovarian cancer.

SOURCE: The Lancet, news release, Sept. 19, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com